Meeting
2023 ASCO Annual Meeting
A randomized, open-label, phase 2 study evaluating abemaciclib in combination with irinotecan and temozolomide in participants with relapsed or refractory Ewing sarcoma.
Authors
Gertjan VAN HAL
Eli Lilly and Company, Indianapolis, IN
Gertjan VAN HAL , Alba Rubio-San-Simón , Chitose Ogawa , Antonio Juan-Ribelles , Holly Knoderer , Jeremy Howard Lewin
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Bone Tumors
Clinical Trial Registration Number
NCT05440786
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS11580)
DOI
10.1200/JCO.2023.41.16_suppl.TPS11580
Abstract #
TPS11580
Poster Bd #
513b
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Two schedules of vincristine, irinotecan and temozolomide (VIT) for patients with relapsed or refractory Ewing sarcoma: A randomized controlled phase 2 trial.
First Author: Jie Xu
Poster
2023 ASCO Annual Meeting
Recommended phase 2 dose (RP2D) for abemaciclib in combination with irinotecan (IRN) and temozolomide (TMZ) in pediatric patients with relapsed/refractory solid tumors (JPCS Part A).
First Author: Álvaro Lassaletta
Poster
2023 ASCO Annual Meeting
Phase 1b/2 study of abemaciclib combined with chemoimmunotherapy in pediatric and young adult patients with relapsed/refractory neuroblastoma (JPCS Part C).
First Author: Emily Gustava Greengard
Poster
2022 ASCO Annual Meeting
Phase 2 study to evaluate palbociclib in combination with irinotecan and temozolomide in pediatric patients with recurrent or refractory Ewing sarcoma.
First Author: Theodore Willis Laetsch